Modality
Radioligand
MOA
CAR-T CD19
Target
GIP-R
Pathway
mTOR
PSP
Development Pipeline
Preclinical
~May 2012
→ ~Aug 2013
Phase 1
~Nov 2013
→ ~Feb 2015
Phase 2
~May 2015
→ ~Aug 2016
Phase 3
~Nov 2016
→ ~Feb 2018
NDA/BLA
~May 2018
→ ~Aug 2019
Approved
Nov 2019
→ Jul 2025
ApprovedCurrent
NCT05654950
1,918 pts·PSP
2019-11→2025-07·Not yet recruiting
1,918 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2025-07-238mo agoPh3 Readout· PSP
Trial Timeline
Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3
Approved
Not yet…
Catalysts
Ph3 Readout
2025-07-23 · 8mo ago
PSP
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05654950 | Approved | PSP | Not yet recr... | 1918 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Datoglumide | AbbVie | Approved | CFTR | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R |